


BIOPHYTIS - Live Healthier Longer Revenue
Biotechnology Research • Paris, Île-de-France, France • 21-50 Employees
BIOPHYTIS - Live Healthier Longer revenue & valuation
| Annual revenue | $21,300,000 |
| Revenue per employee | $923,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $68,000,000 |
| Total funding | $11,400,000 |
Key Contacts at BIOPHYTIS - Live Healthier Longer
Chiara Baccelli
Chief Pharmaceutical Officer & Qa Director
Pierre J. Dilda
Chief Scientific Officer, Ip Director
Francoise Pestretzoff
Marketing And Sales Director
Stanislas Veillet
Owner
Company overview
| Headquarters | 4, place Jussieu, Paris, Ile de France 75005, FR |
| Phone number | +3320062025 |
| Website | |
| SIC | 283 |
| Keywords | Biotechnology, Drug, Ophtalmology, Muscle Disorders |
| Founded | 2006 |
| Employees | 21-50 |
| Socials |
BIOPHYTIS - Live Healthier Longer Email Formats
BIOPHYTIS - Live Healthier Longer uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@biophytis.com), used 76.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@biophytis.com | 76.9% |
{first name}.{last name} | john.doe@biophytis.com | 23.1% |
About BIOPHYTIS - Live Healthier Longer
Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, with promising results in a Phase 2 clinical study (SARA) conducted in the United States and Europe A pediatric formulation of Ruvembri is being developed with IND granted in the US and Belgium (MYODA) for the treatment of Duchenne Muscular Dystrophy (DMD).
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
BIOPHYTIS - Live Healthier Longer has 12 employees across 6 departments.
Departments
Number of employees
Funding Data
Explore BIOPHYTIS - Live Healthier Longer's funding history, including investment rounds, total capital raised, and key backers.
BIOPHYTIS - Live Healthier Longer Tech Stack
Discover the technologies and tools that power BIOPHYTIS - Live Healthier Longer's digital infrastructure, from frameworks to analytics platforms.
Caching
JavaScript libraries
JavaScript libraries
Page builders
JavaScript libraries
Analytics
SEO
JavaScript libraries
Programming languages
Blogs
Analytics
Frequently asked questions
4.8
40,000 users



